Alkem Laboratories Limited (ALKEM.BO)
INR 4835.45
(2.88%)
INR 4835.45
(2.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.6 Billion INR | -114.33% |
| 2022 | 11.22 Billion INR | -53.9% |
| 2021 | 24.36 Billion INR | 56.72% |
| 2020 | 15.54 Billion INR | 0.49% |
| 2019 | 15.46 Billion INR | 122.54% |
| 2018 | 6.95 Billion INR | -16.35% |
| 2017 | 8.3 Billion INR | 68.6% |
| 2016 | 4.92 Billion INR | -7.14% |
| 2015 | 5.3 Billion INR | -54.7% |
| 2014 | 11.71 Billion INR | 26.21% |
| 2013 | 9.28 Billion INR | 14.73% |
| 2012 | 8.08 Billion INR | 347.17% |
| 2011 | -3.27 Billion INR | 55.36% |
| 2010 | -7.33 Billion INR | -23.84% |
| 2009 | -5.92 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 FY | -1.6 Billion INR | -114.33% |
| 2023 Q1 | 11.43 Billion INR | 1.81% |
| 2023 Q2 | 11.22 Billion INR | -1.84% |
| 2023 Q4 | -1.6 Billion INR | -104.46% |
| 2023 Q3 | 36.09 Billion INR | 221.69% |
| 2022 FY | 11.22 Billion INR | -53.9% |
| 2022 Q4 | 11.22 Billion INR | -59.24% |
| 2022 Q3 | 27.55 Billion INR | 63.41% |
| 2022 Q2 | 16.86 Billion INR | 28.41% |
| 2022 Q1 | 13.13 Billion INR | -46.1% |
| 2021 Q2 | 13.97 Billion INR | -20.3% |
| 2021 Q1 | 17.53 Billion INR | 12.82% |
| 2021 Q3 | 25.69 Billion INR | 83.88% |
| 2021 FY | 24.36 Billion INR | 56.72% |
| 2021 Q4 | 24.36 Billion INR | -5.21% |
| 2020 Q1 | 4.6 Billion INR | -70.24% |
| 2020 Q3 | 16.17 Billion INR | 29.88% |
| 2020 Q4 | 15.54 Billion INR | -3.93% |
| 2020 Q2 | 12.45 Billion INR | 170.63% |
| 2020 FY | 15.54 Billion INR | 0.49% |
| 2019 Q1 | 6.54 Billion INR | -5.87% |
| 2019 Q4 | 15.46 Billion INR | 31.24% |
| 2019 Q2 | 11.06 Billion INR | 69.19% |
| 2019 Q3 | 11.78 Billion INR | 6.47% |
| 2019 FY | 15.46 Billion INR | 122.54% |
| 2018 Q1 | 5.32 Billion INR | -35.91% |
| 2018 Q4 | 6.95 Billion INR | 8.83% |
| 2018 Q3 | 6.38 Billion INR | -27.35% |
| 2018 FY | 6.95 Billion INR | -16.35% |
| 2018 Q2 | 8.79 Billion INR | 65.07% |
| 2017 Q4 | 8.3 Billion INR | -23.27% |
| 2017 FY | 8.3 Billion INR | 68.6% |
| 2017 Q1 | 5.12 Billion INR | 4.09% |
| 2017 Q2 | 8.8 Billion INR | 71.58% |
| 2017 Q3 | 10.82 Billion INR | 23.03% |
| 2016 Q3 | 12.62 Billion INR | 139.78% |
| 2016 Q1 | 9.92 Billion INR | 86.95% |
| 2016 FY | 4.92 Billion INR | -7.14% |
| 2016 Q2 | 5.26 Billion INR | -46.92% |
| 2016 Q4 | 4.92 Billion INR | -60.98% |
| 2015 Q2 | 4.28 Billion INR | 0.0% |
| 2015 Q4 | 5.3 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 5.3 Billion INR | -54.7% |
| 2014 Q4 | 11.71 Billion INR | 0.0% |
| 2014 FY | 11.71 Billion INR | 26.21% |
| 2014 Q1 | 2.4 Billion INR | 0.0% |
| 2013 FY | 9.28 Billion INR | 14.73% |
| 2012 FY | 8.08 Billion INR | 347.17% |
| 2011 FY | -3.27 Billion INR | 55.36% |
| 2010 FY | -7.33 Billion INR | -23.84% |
| 2009 FY | -5.92 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 141.631% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 143.576% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 43.384% |
| Granules India Limited | 9.28 Billion INR | 117.33% |
| Indoco Remedies Limited | 6.47 Billion INR | 124.851% |
| Achyut Healthcare Limited | -3.74 Million INR | -42863.161% |
| Ajanta Pharma Limited | -954.9 Million INR | -68.541% |
| Alpa Laboratories Limited | 35.36 Million INR | 4651.084% |
| Brooks Laboratories Limited | 49.48 Million INR | 3352.299% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 67.892% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 148.785% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -39.011% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 112.463% |
| Eris Lifesciences Limited | 13.8 Billion INR | 111.657% |
| FDC Limited | -57.75 Million INR | -2686.743% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 62.443% |
| Gufic Biosciences Limited | 3.19 Billion INR | 150.383% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 61.248% |
| Ipca Laboratories Limited | 11.41 Billion INR | 114.099% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -15.79% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 183.263% |
| Lasa Supergenerics Limited | 205.79 Million INR | 882.025% |
| Laurus Labs Limited | 24.38 Billion INR | 106.6% |
| Lupin Limited | 17.19 Billion INR | 109.361% |
| Mankind Pharma Limited | -9.9 Billion INR | 83.757% |
| Medicamen Biotech Limited | 160.31 Million INR | 1103.892% |
| Medico Remedies Limited | 78.67 Million INR | 2145.579% |
| Megasoft Limited | 1.28 Billion INR | 225.191% |
| NATCO Pharma Limited | -5.81 Billion INR | 72.333% |
| Piramal Pharma Limited | 42.27 Billion INR | 103.807% |
| RPG Life Sciences Limited | -364.7 Million INR | -341.294% |
| Sigachi Industries Limited | 859.94 Million INR | 287.151% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 97.779% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 1210.115% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 3582.721% |
| Unichem Laboratories Limited | 931.91 Million INR | 272.698% |
| Wanbury Limited | 1.1 Billion INR | 245.532% |
| Windlas Biotech Limited | -273.04 Million INR | -489.437% |
| ZIM Laboratories Limited | 983.6 Million INR | 263.623% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 141.14% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -70.886% |
| Divi's Laboratories Limited | -39.77 Billion INR | 95.953% |
| Hester Biosciences Limited | 2.29 Billion INR | 170.257% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 31.457% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -546.886% |
| Bal Pharma Limited | 1.26 Billion INR | 227.37% |
| Strides Pharma Science Limited | 23.25 Billion INR | 106.92% |
| Venus Remedies Limited | -267.7 Million INR | -501.195% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 161.618% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 126.138% |
| Shilpa Medicare Limited | 9.06 Billion INR | 117.745% |
| Aarti Drugs Limited | 5.54 Billion INR | 129.007% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -46.136% |
| Suven Life Sciences Limited | -1.63 Billion INR | 1.427% |
| Ind-Swift Limited | 9.5 Billion INR | 116.926% |
| Valiant Laboratories Limited | -295.03 Million INR | -445.5% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 157.047% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 116.047% |
| Themis Medicare Limited | 764.96 Million INR | 310.39% |
| Hikal Limited | 7.96 Billion INR | 120.201% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 105.056% |
| Sequent Scientific Limited | 4.17 Billion INR | 138.515% |
| Novartis India Limited | -5.89 Billion INR | 72.681% |
| Wockhardt Limited | 18.27 Billion INR | 108.809% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 105.945% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -8624.927% |
| Neuland Laboratories Limited | -214.05 Million INR | -651.852% |
| Morepen Laboratories Limited | -231.17 Million INR | -596.186% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 1440.731% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 264.929% |